Posts by Mike Mooney
GemVax & KAEL Announces Results from Phase 2 PSP Study
South Korean biopharmaceutical company GemVax & Kael announced the results from its Phase 2 clinical trial of a potential drug for progressive supranuclear palsy Richardson’s syndrome (PSP-RS, a PSP subtype).…
Read MoreAFTD Director of Research Engagement Shana Dodge Presents at 2025 NORD Breakthrough Summit Lightning Round
AFTD Director of Research Engagement Shana Dodge, PhD, presented on an AFTD-hosted industry advisory panel during the 2025 National Organization of Rare Disorders (NORD) Breakthrough Summit Lightning Round. Dr. Dodge’s…
Read MoreDear HelpLine: Sharing the Diagnosis
Dear HelpLine, My wife was diagnosed with FTD this past year and we will be seeing family over the holidays. This will be the first time we will be seeing…
Read MoreUnderstanding and Responding to FTD Behaviors
Behavioral symptoms associated with FTD often present significant challenges, not only for the individual diagnosed but also for their care partners. FTD behaviors, such as disinhibition, apathy, compulsivity, or loss…
Read MoreAFTD Grantee Leads Basic Science Study Exploring Role of Protein in Tau-Based Disorders like CBD
A recent study examines the role of chromogranin A (CgA) in disorders caused by dysfunctional tau protein. The study expands our foundational knowledge of these forms of FTD and opens…
Read MorePave the Path Forward This Giving Tuesday
AFTD Persons with FTD Advisory Council member Sandy Howe and her husband, Dirk, are sharing their story this Giving Tuesday to raise awareness about FTD and provide support for other…
Read More
